Ceramides Linked to Kidney Injury: New Drug Shows Promise in Mice | Cell Metabolism Study

Acute kidney injury (AKI), a serious and potentially life-threatening condition affecting short-term kidney function, impacts more than half of all patients in intensive care. Currently, there are no approved medications specifically designed to treat AKI, leaving a critical gap in care. However, new research from the University of Utah Health (U of U Health) offers a promising avenue for treatment, identifying fatty molecules called ceramides as key triggers of AKI and demonstrating a potential reversal of kidney damage in mice.

Ceramides: A Newly Identified Culprit in Kidney Injury

Researchers have discovered that AKI is initiated by the buildup of ceramides, which inflict damage on the mitochondria – the energy-producing components – within kidney cells. This finding builds on previous operate from the same lab showing that ceramides can also harm the heart and liver. By utilizing a drug candidate designed to alter ceramide metabolism, the research team was able to preserve mitochondrial integrity and prevent kidney injury in mouse models. “We completely reversed the pathology of acute kidney injury by inactivating ceramides,” explained Scott Summers, PhD, distinguished professor and Chair of the Department of Nutrition and Integrative Physiology at the University of Utah College of Health, and senior author of the study published in Cell Metabolism.

The team’s findings suggest that ceramide levels spike dramatically following kidney injury, both in mice and in human urine samples. Rebekah Nicholson, PhD, the first author of the study, noted that the severity of the injury correlates directly with ceramide levels: “The worse the kidney injury is, the higher the ceramide levels will be.” This observation raises the possibility of using ceramide levels in urine as an early biomarker to identify patients at risk of developing AKI, particularly those undergoing procedures like heart surgery, where the risk is elevated.

Genetic Modification and Drug Candidates Show Promise in Mice

The researchers initially explored the impact of altering ceramide production through genetic modification. By modifying the genetic program controlling ceramide production in mice, they created a model that was remarkably resistant to AKI, even under conditions that typically cause severe damage. This “super mouse” model demonstrated the protective effect of reducing ceramide levels.

Building on this success, the team then tested a ceramide-lowering drug candidate developed by Centaurus Therapeutics, a company co-founded by Dr. Summers. Mice treated with the drug prior to kidney injury experienced significant protection, maintaining normal kidney function, exhibiting normal activity levels, and displaying kidneys that appeared nearly normal under microscopic examination. The researchers emphasize that the model used to induce kidney injury places extreme stress on the kidneys, making the protective effects of the drug even more remarkable.

How Ceramides Damage Kidney Cells: A Mitochondrial Focus

The study revealed that ceramides directly harm mitochondria, disrupting their structure and function. Damaged mitochondria in kidney cells become distorted and less efficient at producing energy. By adjusting ceramide production – either genetically or with the drug candidate – the researchers were able to maintain mitochondrial integrity and function, even under stressful conditions. This highlights the critical role of mitochondrial health in preventing AKI.

Translating Findings to Humans: Cautious Optimism and Ongoing Research

Dr. Summers clarified that the compound used in the study is related to, but not identical to, a ceramide-lowering drug currently undergoing human clinical trials. He stressed the importance of caution, noting that results observed in mice do not always translate to humans and that further research is essential to confirm safety and efficacy. “We’re thrilled by how protective this backup compound was, but it’s still preclinical,” he said. “We need to be cautious and do our due diligence to develop sure this approach is truly safe before moving it into patients.”

Despite the need for further investigation, the findings are encouraging. If the results are replicated in humans, the drug could potentially be administered proactively to individuals at high risk of AKI, such as those preparing for heart surgery, where approximately one in four patients experience the condition. The potential benefits extend beyond AKI, as the drug’s mechanism of action – maintaining mitochondrial health – may have relevance for other disorders linked to mitochondrial dysfunction, including heart failure, diabetes, and fatty liver disease. University of Utah Health news reports that Summers believes restoring mitochondrial health could have “enormous” implications for a wide range of diseases.

Understanding the Role of DES1 in Ceramide Metabolism

Further research, published in PubMed, delves deeper into the specific mechanisms by which ceramides contribute to AKI. This study identifies dihydroceramide desaturase 1 (DES1) as a key enzyme involved in the production of lipotoxic ceramides within the kidney’s proximal tubules. Researchers found that genetically ablating DES1, or using novel DES1 inhibitors, preserved mitochondrial integrity and prevented kidney injury in mice following ischemia reperfusion – a common cause of AKI. This research highlights DES1 as a potential therapeutic target for AKI.

What’s Next: Clinical Trials and Broader Implications

The next crucial step involves conducting clinical trials to evaluate the safety and efficacy of ceramide-lowering drugs in humans. These trials will be essential to determine whether the promising results observed in mice translate to clinical benefit for patients at risk of or suffering from AKI. Researchers will also continue to investigate the potential of this approach for treating other diseases linked to mitochondrial dysfunction. The team is also exploring the potential of urinary ceramide levels as a diagnostic tool, which could allow for earlier intervention and improved patient outcomes. Ongoing research will focus on refining the drug candidates and identifying the optimal dosage and timing for administration to maximize therapeutic benefit.